CN110015996B - Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside - Google Patents

Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside Download PDF

Info

Publication number
CN110015996B
CN110015996B CN201910374991.2A CN201910374991A CN110015996B CN 110015996 B CN110015996 B CN 110015996B CN 201910374991 A CN201910374991 A CN 201910374991A CN 110015996 B CN110015996 B CN 110015996B
Authority
CN
China
Prior art keywords
substituted
reaction
spirocyclic
synthesizing
carbocyclic nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910374991.2A
Other languages
Chinese (zh)
Other versions
CN110015996A (en
Inventor
郝二军
张庆
郭海明
张齐英
苏富赢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Normal University
Original Assignee
Henan Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Normal University filed Critical Henan Normal University
Priority to CN201910374991.2A priority Critical patent/CN110015996B/en
Publication of CN110015996A publication Critical patent/CN110015996A/en
Application granted granted Critical
Publication of CN110015996B publication Critical patent/CN110015996B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Saccharide Compounds (AREA)

Abstract

本发明公开了一种合成2′‑螺环基取代的三元碳环核苷的方法,属于有机化学技术领域。α‑嘧啶取代的丙烯酸酯和α‑氯代环烷酮为原料,通过迈克反应启动的环丙环化反应,合成了系列结构新型螺环核苷。本发明采用原料简单易得,在合成过程中避免了以往方法中步骤繁多、产率低和普适性差的缺点。通过该方法合成的螺环嘧啶核苷产率高达84%,且产物结构丰富。The invention discloses a method for synthesizing a 2'-spirocyclic group-substituted three-membered carbocyclic nucleoside, and belongs to the technical field of organic chemistry. Using α-pyrimidine-substituted acrylate and α-chlorocycloalkanone as raw materials, a series of new spiro nucleosides were synthesized through cyclopropane cyclization initiated by Mike's reaction. The method of the invention adopts simple and easy-to-obtain raw materials, and avoids the disadvantages of numerous steps, low yield and poor universality in the previous method in the synthesis process. The yield of spirocyclic pyrimidine nucleosides synthesized by this method is as high as 84%, and the product structure is rich.

Description

一种合成2′-螺环基取代三元碳环核苷的方法A kind of method for synthesizing 2'-spirocyclyl-substituted three-membered carbocyclic nucleosides

技术领域technical field

本发明涉及螺环核苷的合成方法,具体涉及采用环丙环化反应合成2′-螺环基取代三元碳环核苷的方法,属于有机化学技术领域。The invention relates to a method for synthesizing spirocyclic nucleosides, in particular to a method for synthesizing 2'-spirocyclic group-substituted three-membered carbocyclic nucleosides by cyclopropane cyclization, and belongs to the technical field of organic chemistry.

背景技术Background technique

螺环核苷大多都属于构象限制核苷,其分子构象组成较为单一。底物与酶进行结合前,酶活性中心构象会先根据底物构象发生变化,接着再与底物契合形成活性络合物,构象单一的底物会更有利于酶活性中心构象转化,因此发展构象限制核苷相对于非构象限制核苷药物具有一定的优势。目前,公开报道的合成螺环核苷方法步骤繁琐且普适性差,主要是在糖环4′位引入螺环,典型的代表性合成路线如下:Most of the spiro nucleosides are conformationally restricted nucleosides, and their molecular conformation is relatively simple. Before the substrate is combined with the enzyme, the conformation of the active center of the enzyme will first change according to the conformation of the substrate, and then it will fit with the substrate to form an active complex. Conformation-restricted nucleosides have certain advantages over non-conformation-restricted nucleoside drugs. At present, the publicly reported methods for synthesizing spirocyclic nucleosides are cumbersome and poorly universal, mainly introducing a spiro ring at the 4' position of the sugar ring. A typical representative synthetic route is as follows:

1、螺环嘧啶核苷G和F的合成,反应方程式如下:1, the synthesis of spirocyclic pyrimidine nucleosides G and F, the reaction equation is as follows:

Figure BDA0002051333090000011
Figure BDA0002051333090000011

该方法合成步骤长,C-N键缩合时需要用到昂贵的金属钯催化,所得产物为两种构型的异构体混合物,分离比较困难。The method has long synthesis steps, expensive metal palladium catalysis is required for the condensation of C-N bonds, and the obtained product is a mixture of isomers of two configurations, which is difficult to separate.

2、螺环嘧啶核苷D的合成,反应方程式如下:2, the synthesis of spirocyclic pyrimidine nucleoside D, the reaction equation is as follows:

Figure BDA0002051333090000021
Figure BDA0002051333090000021

该方法合成步骤长,底物普适性差,先是采用邻溴苯胺缩合,最终采用n-Bu3SnH方法自由基脱溴,增加了不必要的反应。This method has long synthesis steps and poor substrate universality. First, o-bromoaniline is used for condensation, and finally, the n-Bu 3 SnH method is used for free radical debromination, which increases unnecessary reactions.

鉴于螺环核苷作为构象限制核苷的重要组成部分,因此寻找简单高效合成螺环核苷的方法仍非常必要。Given that spiro nucleosides are an important part of conformationally restricted nucleosides, it is still necessary to find a simple and efficient method for the synthesis of spiro nucleosides.

发明内容SUMMARY OF THE INVENTION

为了克服上述缺陷,本发明提供了一种合成2′-螺环基取代三元碳环核苷的方法。以α-嘧啶取代丙烯酸酯和α-氯代环烷酮为原料,在无机碱作用下通过迈克反应启动环丙环化反应,合成了系列新型螺环核苷化合物。该方法为合成螺环核苷化合物提供了一种简便、廉价、高效的途径。In order to overcome the above-mentioned defects, the present invention provides a method for synthesizing 2'-spirocyclyl-substituted three-membered carbocyclic nucleosides. Using α-pyrimidine substituted acrylate and α-chlorocycloalkanone as raw materials, a series of new spirocyclic nucleoside compounds were synthesized by Mike reaction initiating cyclopropane cyclization under the action of inorganic base. This method provides a simple, cheap and efficient way for the synthesis of spirocyclic nucleoside compounds.

一种合成2′-螺环基取代三元碳环核苷的方法,其特征在于,包括如下操作:以α-嘧啶取代丙烯酸酯1与α-氯代环烷酮2为原料,在碱作用下,有机溶剂中反应得到螺环嘧啶核苷3。反应方程式如下:A method for synthesizing 2'-spirocyclyl-substituted three-membered carbocyclic nucleosides, comprising the following operations: using α-pyrimidine-substituted acrylate 1 and α-chlorocycloalkanone 2 as raw materials, and under the action of a base Under the following conditions, the spirocyclic pyrimidine nucleoside 3 is obtained by the reaction in an organic solvent. The reaction equation is as follows:

Figure BDA0002051333090000022
Figure BDA0002051333090000022

其中,R1选自氢、C1-C6烷基、烷氧基;R2选自C1-C4烷基、苄基、苯基;R3选自苯甲酰基和叔丁氧羰基;具体而言,R1选自甲基、乙基、氢、卤素、甲氧基或三氟甲基;R2选自甲基、乙基、叔丁基、苯基或苄基。Wherein, R 1 is selected from hydrogen, C1-C6 alkyl, alkoxy; R 2 is selected from C1-C4 alkyl, benzyl, phenyl; R 3 is selected from benzoyl and tert-butoxycarbonyl; specifically , R 1 is selected from methyl, ethyl, hydrogen, halogen, methoxy or trifluoromethyl; R 2 is selected from methyl, ethyl, tert-butyl, phenyl or benzyl.

进一步地,在上述技术方案中,所述α-嘧啶取代丙烯酸酯1、α-氯代环烷酮2与碱摩尔比为1:1.2-1.5:1.2-2.0,优选摩尔比为1:1.5:1.5。Further, in the above technical scheme, the molar ratio of the α-pyrimidine substituted acrylate 1, α-chlorocycloalkanone 2 and the base is 1:1.2-1.5:1.2-2.0, and the preferred molar ratio is 1:1.5: 1.5.

进一步地,在上述技术方案中,所述溶剂选自乙腈、甲醇、二氯甲烷、四氢呋喃、甲苯或二氧六环。Further, in the above technical solution, the solvent is selected from acetonitrile, methanol, dichloromethane, tetrahydrofuran, toluene or dioxane.

进一步地,在上述技术方案中,所述碱选自:碳酸钠、碳酸钾、碳酸铯、乙酸钠、DBU、叔丁醇钠或叔丁醇钾。优选碳酸钾、DBU、碳酸铯或叔丁醇钾。Further, in the above technical scheme, the base is selected from: sodium carbonate, potassium carbonate, cesium carbonate, sodium acetate, DBU, sodium tert-butoxide or potassium tert-butoxide. Potassium carbonate, DBU, cesium carbonate or potassium tert-butoxide are preferred.

进一步地,在上述技术方案中,反应温度选自-30℃到50℃。Further, in the above technical solution, the reaction temperature is selected from -30°C to 50°C.

进一步地,在上述技术方案中,整个反应过程无需惰性气体保护。Further, in the above technical solution, the entire reaction process does not require protection of inert gas.

进一步地,在上述技术方案中,螺环嘧啶产物3进一步衍生反应可以得到不同类型的衍生产物4或5。反应方程式如下:Further, in the above technical scheme, the spirocyclic pyrimidine product 3 is further derivatized to obtain different types of derivative products 4 or 5. The reaction equation is as follows:

Figure BDA0002051333090000031
Figure BDA0002051333090000031

其中,还原剂选自硼氢化钠或四氢铝锂;脱保护反应选用氨/甲醇或三氟乙酸。具体而言,还原反应溶剂选自二氯甲烷和甲醇混合溶剂下进行,优选体积比例二氯甲烷:甲醇=2:1。氨/甲醇溶液用于脱除R3为苯甲酰基保护,三氟乙酸用用于脱除R3为叔丁氧羰基保护。Wherein, the reducing agent is selected from sodium borohydride or lithium aluminum tetrahydrogen; the deprotection reaction is selected from ammonia/methanol or trifluoroacetic acid. Specifically, the reduction reaction solvent is selected from a mixed solvent of dichloromethane and methanol, and the volume ratio is preferably dichloromethane:methanol=2:1. Ammonia/methanol solution was used to remove R 3 for benzoyl protection, and trifluoroacetic acid was used to remove R 3 for tert-butoxycarbonyl protection.

发明有益效果:Invention Beneficial Effects:

该方法为合成螺环核苷化合物提供了一种简便、廉价、高效的途径。采用的原料简单易得,在合成过程中避免了以往方法中步骤繁多、产率低和普适性差的缺点。通过该方法合成的螺环嘧啶核苷产率高达84%,且产物结构丰富。This method provides a simple, cheap and efficient way for the synthesis of spirocyclic nucleoside compounds. The raw materials used are simple and easy to obtain, and in the synthesis process, the disadvantages of many steps, low yield and poor universality in the previous method are avoided. The yield of spirocyclic pyrimidine nucleosides synthesized by this method is as high as 84%, and the product structure is rich.

具体实施方式Detailed ways

实施例1Example 1

Figure BDA0002051333090000041
Figure BDA0002051333090000041

Figure BDA0002051333090000042
Figure BDA0002051333090000042

Figure BDA0002051333090000051
Figure BDA0002051333090000051

a除非特别说明,反应的步骤如下:1a(0.1mmol),2a(1.5equiv),碱(1.5equiv)在空气中反应5小时。b分离收率c叔丁醇钾(1.2equiv)d叔丁醇钾(2.0equiv)e1h f0.5h。 a Unless otherwise specified, the reaction steps are as follows: 1a (0.1 mmol), 2a (1.5 equiv), and base (1.5 equiv) were reacted in air for 5 hours. b Isolated yield c Potassium tert-butoxide (1.2 equiv) d Potassium tert-butoxide (2.0 equiv) e 1h f 0.5h.

在反应条件的筛选过程中,首先考察了碱对该反应的影响(entries 1-6)。其次对溶剂和温度进行了考察,通过对产率进行对比,最终确定了叔丁醇钾为最优碱,乙腈为最优溶剂,-20℃为最佳温度。During the screening of reaction conditions, the effect of bases on the reaction was first investigated (entries 1-6). Secondly, the solvent and temperature were investigated. By comparing the yields, it was finally determined that potassium tert-butoxide was the optimal base, acetonitrile was the optimal solvent, and -20°C was the optimal temperature.

典型的反应条件操作:Typical reaction conditions for operation:

在反应瓶内,将α-嘧啶取代丙烯酸甲酯1a(0.1mmol)和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应时间为0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3aa,收率83%。In a reaction flask, α-pyrimidine substituted methyl acrylate 1a (0.1 mmol) and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and placed at -20 °C for 10 minutes with stirring and cooling, and then α-chloro Substituted cycloalkanone 2a (0.15mmol) was added to the reaction solution for reaction, and the reaction time was 0.5h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3aa was obtained by column chromatography with a yield of 83%.

3aa:White solid,m.p.227.2-232.5℃;33mg,83%yield;3aa: White solid, m.p. 227.2-232.5℃; 33mg, 83% yield;

1H NMR(400MHz,CDCl3):7.90-7.88(d,J=8.0Hz,2H),7.62(d,J=7.6Hz,1H),7.48(t,J=8.0Hz,2H),7.06(d,J=3.2Hz,1H),3.77(s,3H),2.44(m,1H),2.36-2.27(m,1H),2.27-2.17(m,2H),2.08(m,2H),2.01-1.95(m,4H),1.89(s,1H).13C NMR(100MHz,CDCl3):212.1,167.7,139.4,135.0,131.5,130.7,129.1,111.5,77.3,53.6,50.4,42.6,38.9,28.5,26.2,20.2,12.7.HRMS(ESI-TOF):exact mass calcd for C21H20N2NaO6(M+Na)+requires m/z 419.1214,found m/z 419.1206. 1 H NMR (400 MHz, CDCl 3 ): 7.90-7.88 (d, J=8.0 Hz, 2H), 7.62 (d, J=7.6 Hz, 1H), 7.48 (t, J=8.0 Hz, 2H), 7.06 ( d, J=3.2Hz, 1H), 3.77(s, 3H), 2.44(m, 1H), 2.36-2.27(m, 1H), 2.27-2.17(m, 2H), 2.08(m, 2H), 2.01 -1.95(m, 4H), 1.89(s, 1H). 13 C NMR (100MHz, CDCl 3 ): 212.1, 167.7, 139.4, 135.0, 131.5, 130.7, 129.1, 111.5, 77.3, 53.6, 50.4, 42.6, 38.9 ,28.5,26.2,20.2,12.7.HRMS(ESI-TOF):exact mass calcd for C 21 H 20 N 2 NaO 6 (M+Na) + requires m/z 419.1214,found m/z 419.1206.

实施例2Example 2

在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代丙烯酸乙酯1b和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ba,收率85%。In a 10 mL vacuum tube, α-(3-benzoyl-5-methyl)uracil-substituted ethyl acrylate 1b and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and stirred at -20 °C After cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ba was obtained by column chromatography with a yield of 85%.

实施例3Example 3

在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代丙烯酸叔丁酯1c和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。通过TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ca,收率83%。In a 10 mL vacuum tube, dissolve α-(3-benzoyl-5-methyl)uracil-substituted tert-butyl acrylate 1c and 1.5 eq (0.15 mmol) potassium tert-butoxide in 1 mL of acetonitrile and place at -20°C After stirring and cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was monitored by TLC for completion, quenched with water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ca was obtained by column chromatography with a yield of 83%.

实施例4Example 4

在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代的丙烯酸苄酯1d和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应时间为0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3da,收率83%。In a 10 mL vacuum tube, dissolve α-(3-benzoyl-5-methyl)uracil-substituted benzyl acrylate 1d and 1.5 eq (0.15 mmol) potassium tert-butoxide in 1 mL of acetonitrile and place at -20°C After stirring and cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction, and the reaction time was 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3da was obtained by column chromatography with a yield of 83%.

实施例5Example 5

在10mL真空管中,将α-(3-叔丁氧羰基-5-甲基)尿嘧啶取代丙烯酸甲酯1f和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3fa,收率79%。In a 10 mL vacuum tube, dissolve α-(3-tert-butoxycarbonyl-5-methyl)uracil substituted methyl acrylate 1f and 1.5 eq (0.15 mmol) potassium tert-butoxide in 1 mL of acetonitrile and place at -20°C After stirring and cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3fa was obtained by column chromatography with a yield of 79%.

3fa:White solid,m.p.180.0-185.4℃;31mg,79%yield;3fa: White solid, m.p.180.0-185.4℃; 31mg, 79% yield;

1H NMR(600MHz,CDCl3):6.94-6.92(m,1H),3.74(s,3H),2.65-2.44(m,2H),2.33-2.18(m,3H),2.03(d,J=4.8Hz,1H),1.93-1.92(m,3H),1.89(d,J=5.4Hz,1H),1.68(s,1H),1.56(s,9H).13C NMR(100MHz,CDCl3):211.2,167.8,147.7,139.0,111.1,86.5,53.6,50.6,42.4,38.8,28.6,27.5,26.3,20.2,12.7.HRMS(ESI-TOF):exact mass calcd forC19H24N2NaO7(M+Na)+requires m/z 415.1476,found m/z 415.1471. 1 H NMR (600 MHz, CDCl 3 ): 6.94-6.92 (m, 1H), 3.74 (s, 3H), 2.65-2.44 (m, 2H), 2.33-2.18 (m, 3H), 2.03 (d, J= 4.8Hz, 1H), 1.93-1.92(m, 3H), 1.89(d, J=5.4Hz, 1H), 1.68(s, 1H), 1.56(s, 9H). 13 C NMR (100MHz, CDCl 3 ) :211.2,167.8,147.7,139.0,111.1,86.5,53.6,50.6,42.4,38.8,28.6,27.5,26.3,20.2,12.7.HRMS(ESI-TOF):exact mass calcd forC 19 H 24 N 2 NaO 7 ( M+Na) + requires m/z 415.1476, found m/z 415.1471.

实施例6Example 6

在10mL真空管中,将α-(3-苯甲酰基-5-乙基)尿嘧啶取代丙烯酸甲酯1i和1.5eq(0.15mmol)的叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ia,收率81%。In a 10 mL vacuum tube, dissolve α-(3-benzoyl-5-ethyl)uracil substituted methyl acrylate 1i and 1.5 eq (0.15 mmol) of potassium tert-butoxide in 1 mL of acetonitrile and place at -20°C After stirring and cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ia was obtained by column chromatography with a yield of 81%.

3ia Colorless oil,33mg,81%yield;3ia Colorless oil, 33mg, 81% yield;

1H NMR(400MHz,CDCl3):7.88(d,J=7.6Hz,2H),7.61(d,J=7.2Hz,1H),7.47(d,J=7.6Hz,2H),6.98(s,1H),3.77(s,3H),2.47-2.37(m,3H),2.35-2.18(m,3H),2.14-2.08(m,2H),1.96(d,J=5.2Hz,1H),1.90-1.85(m,1H),1.17(t,J=7.2Hz,3H).13C NMR(100MHz,CDCl3):212.1,168.6,167.7,138.5,135.0,131.5,130.6,129.1,117.1,53.6,50.5,42.6,38.9,28.5,26.2,20.3,20.1,12.5.HRMS(ESI-TOF):exact mass calcd for C22H22N2NaO6(M+Na)+requires m/z 433.1370,found m/z 433.1365. 1 H NMR (400 MHz, CDCl 3 ): 7.88 (d, J=7.6 Hz, 2H), 7.61 (d, J=7.2 Hz, 1H), 7.47 (d, J=7.6 Hz, 2H), 6.98 (s, 1H), 3.77(s, 3H), 2.47-2.37(m, 3H), 2.35-2.18(m, 3H), 2.14-2.08(m, 2H), 1.96(d, J=5.2Hz, 1H), 1.90 -1.85 (m, 1H), 1.17 (t, J=7.2Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): 212.1, 168.6, 167.7, 138.5, 135.0, 131.5, 130.6, 129.1, 117.1, 53.6, 50.5,42.6,38.9,28.5,26.2,20.3,20.1,12.5.HRMS(ESI-TOF):exact mass calcd for C 22 H 22 N 2 NaO 6 (M+Na) + requires m/z 433.1370,found m/ z 433.1365.

实施例7Example 7

在10mL真空管中,将α-(3-苯甲酰基-5-氟)尿嘧啶取代丙烯酸甲酯1j和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ja,收率68%。In a 10 mL vacuum tube, α-(3-benzoyl-5-fluoro)uracil substituted methyl acrylate 1j and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and placed at -20°C for stirring and cooling After 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ja was obtained by column chromatography with a yield of 68%.

实施例8Example 8

在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代丙烯酸甲酯1a和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环己酮2b(0.15mmol)加至反应液中进行反应,反应时间为12h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ab,收率66%。In a 10 mL vacuum tube, α-(3-benzoyl-5-methyl)uracil substituted methyl acrylate 1a and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and stirred at -20 °C After cooling for 10 minutes, α-chlorocyclohexanone 2b (0.15 mmol) was added to the reaction solution for reaction, and the reaction time was 12 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ab was obtained by column chromatography with a yield of 66%.

实施例9Example 9

在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代丙烯酸甲酯1a和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将0.15mmolα-氯代环庚酮2c加至反应液中进行反应,反应时间为0.5h。TLC监测反应完全,将反应混合物在乙酸乙酯和水之间分配。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ac,收率72%。In a 10 mL vacuum tube, α-(3-benzoyl-5-methyl)uracil substituted methyl acrylate 1a and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and stirred at -20 °C After cooling for 10 minutes, 0.15 mmol of α-chlorocycloheptanone 2c was added to the reaction solution for reaction, and the reaction time was 0.5 h. The reaction was complete by TLC and the reaction mixture was partitioned between ethyl acetate and water. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ac was obtained by column chromatography with a yield of 72%.

3ac:White solid,m.p.213.0-218.4℃;31mg,72%yield;3ac: White solid, m.p. 213.0-218.4℃; 31mg, 72% yield;

1H NMR(400MHz,CDCl3):7.87(d,J=8.0Hz,2H),7.62(t,J=7.2Hz,1H),7.48(t,J=8.0Hz,2H),7.04(s,1H),3.76(s,3H),2.82(t,J=12.0Hz,1H),2.34-2.29(m,1H),2.21-2.15(m,3H),2.00-1.73(m,8H),1.38-1.25(m,2H).13C NMR(100MHz,CDCl3):207.6,168.4,167.6,150.5,139.7,135.0,131.5,130.6,129.1,111.4,53.7,51.3,46.1,44.0,30.6,27.5,27.1,26.4,25.6,12.6.HRMS(ESI-TOF):exact mass calcd for C23H24N2NaO6(M+Na)+requires m/z 447.1527,found m/z 447.1532. 1 H NMR (400 MHz, CDCl 3 ): 7.87 (d, J=8.0 Hz, 2H), 7.62 (t, J=7.2 Hz, 1H), 7.48 (t, J=8.0 Hz, 2H), 7.04 (s, 1H), 3.76(s, 3H), 2.82(t, J=12.0Hz, 1H), 2.34-2.29(m, 1H), 2.21-2.15(m, 3H), 2.00-1.73(m, 8H), 1.38 -1.25(m, 2H). 13 C NMR (100 MHz, CDCl 3 ): 207.6, 168.4, 167.6, 150.5, 139.7, 135.0, 131.5, 130.6, 129.1, 111.4, 53.7, 51.3, 46.1, 44.0, 30.6, 27.5, 27.1,26.4,25.6,12.6.HRMS(ESI-TOF):exact mass calcd for C 23 H 24 N 2 NaO 6 (M+Na) + requires m/z 447.1527,found m/z 447.1532.

实施例10Example 10

根据实施2-9的反应条件和操作,仅改变反应底物,反应结果如下:According to the reaction conditions and operations of implementing 2-9, only the reaction substrate was changed, and the reaction results were as follows:

Figure BDA0002051333090000091
Figure BDA0002051333090000091

实施例11Example 11

在10mL真空管中,加入环丙烷化产物3aa(39.6mg,0.1mmol),并加入二氯甲烷和甲醇体积比为2:1混合溶剂1.5mL,将反应液在-20℃低温反应浴中搅拌冷却10分钟,然后称取硼氢化钠(11.3mg,0.3mmol)缓慢分批加入到反应液中,将反应液在-20℃反应30分钟。TLC检测到反应完全,向反应液中加入0.5mL饱和氯化铵溶液淬灭反应,然后加入二氯甲烷和水进行萃取,柱层析法对产物进行分离纯化,最终得到酮羰基还原产物4aa(24mg,0.06mmol)。In a 10 mL vacuum tube, the cyclopropanation product 3aa (39.6 mg, 0.1 mmol) was added, and 1.5 mL of a mixed solvent of dichloromethane and methanol with a volume ratio of 2:1 was added, and the reaction solution was stirred and cooled in a low temperature reaction bath of -20 °C After 10 minutes, sodium borohydride (11.3 mg, 0.3 mmol) was weighed and slowly added to the reaction solution in batches, and the reaction solution was reacted at -20° C. for 30 minutes. TLC detected that the reaction was complete, 0.5 mL of saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and then dichloromethane and water were added for extraction, and the product was separated and purified by column chromatography to finally obtain the ketone carbonyl reduction product 4aa ( 24 mg, 0.06 mmol).

Figure BDA0002051333090000092
Figure BDA0002051333090000092

4aa:White solid,m.p.175.5-180.1℃;24mg,60%yield;4aa: White solid, m.p.175.5-180.1℃; 24mg, 60% yield;

1H NMR(400MHz,CDCl3):7.97-7.95(m,2H),7.66-7.63(m,1H),7.50(t,J=8.0Hz,2H),7.13(s,1H),3.74(s,3H),3.54(d,J=3.2Hz,1H),2.30(s,1H),2.13-2.02(m,1H),1.99-1.94(m,3H),1.90-1.70(m,6H),1.34(d,J=5.2Hz,1H).13C NMR(150MHz,CDCl3):169.2,167.8,153.5,139.8,135.3,131.2,130.5,129.3,112.8,77.4,53.3,49.8,47.0,32.9,27.9,26.6,20.9,12.6.HRMS(ESI-TOF):exact mass calcd for C21H22N2NaO6(M+Na)+requires m/z 421.1370,found m/z 421.1366. 1 H NMR (400 MHz, CDCl 3 ): 7.97-7.95 (m, 2H), 7.66-7.63 (m, 1H), 7.50 (t, J=8.0 Hz, 2H), 7.13 (s, 1H), 3.74 (s ,3H),3.54(d,J=3.2Hz,1H),2.30(s,1H),2.13-2.02(m,1H),1.99-1.94(m,3H),1.90-1.70(m,6H), 1.34 (d, J=5.2 Hz, 1H). 13 C NMR (150 MHz, CDCl 3 ): 169.2, 167.8, 153.5, 139.8, 135.3, 131.2, 130.5, 129.3, 112.8, 77.4, 53.3, 49.8, 47.0, 32.9, 27.9,26.6,20.9,12.6.HRMS(ESI-TOF):exact mass calcd for C 21 H 22 N 2 NaO 6 (M+Na) + requires m/z 421.1370,found m/z 421.1366.

实施例12Example 12

在10mL真空管中,准确称量4aa(39.8mg,0.1mmol)加入到反应管中,然后塞上橡胶塞并使用封口膜密封,进行氮气交换以保证反应可以在氮气氛围下进行,用针管吸取氨/甲醇溶液(浓度为1mol/L)1mL加入到反应管中,将反应液在室温下进行反应,反应时间为3小时,TLC检测到反应完全,将反应液减压蒸发然后通过柱层析法对产物进行分离纯化,最终得到产物5aa(24mg,0.08mmol)。In a 10mL vacuum tube, accurately weigh 4aa (39.8mg, 0.1mmol) into the reaction tube, then plug it with a rubber stopper and seal it with parafilm, and perform nitrogen exchange to ensure that the reaction can be carried out in a nitrogen atmosphere. Use a syringe to absorb ammonia 1 mL of methanol solution (concentration of 1 mol/L) was added to the reaction tube, and the reaction solution was reacted at room temperature for 3 hours. TLC detected that the reaction was complete. The reaction solution was evaporated under reduced pressure and then passed through column chromatography. The product was isolated and purified to finally obtain product 5aa (24 mg, 0.08 mmol).

Figure BDA0002051333090000101
Figure BDA0002051333090000101

代表性化合物表征数据如下:Representative compound characterization data are as follows:

5aa:White solid,m.p.233.0-238.4℃;26mg,87%yield;5aa: White solid, m.p.233.0-238.4℃; 26mg, 87% yield;

1H NMR(400MHz,CDCl3):9.36(s,1H),7.00(s,1H),4.23(s,1H),3.71(s,3H),3.52(d,J=3.2Hz,1H),2.38(s,1H),2.11(s,1H),1.95-1.72(m,8H),1.69(d,J=5.3Hz,1H),1.27(d,J=5.2Hz,1H).13CNMR(150MHz,CDCl3):169.4,163.4,154.3,140.1,112.7,77.2,53.3,49.3,47.0,32.8,27.9,26.9,20.9,12.5.HRMS(ESI-TOF):exact mass calcd forC14H18N2NaO5(M+Na)+requires m/z 317.1108,found m/z 317.1107. 1 H NMR (400MHz, CDCl 3 ): 9.36(s,1H), 7.00(s,1H), 4.23(s,1H), 3.71(s,3H), 3.52(d, J=3.2Hz,1H), 2.38(s, 1H), 2.11(s, 1H), 1.95-1.72(m, 8H), 1.69(d, J=5.3Hz, 1H), 1.27(d, J=5.2Hz, 1H). 13 CNMR( 150MHz, CDCl 3 ): 169.4, 163.4, 154.3, 140.1, 112.7, 77.2, 53.3, 49.3, 47.0, 32.8, 27.9, 26.9, 20.9, 12.5.HRMS(ESI-TOF): exact mass calcd forC 14 H 18 N 2 NaO 5 (M+Na) + requires m/z 317.1108, found m/z 317.1107.

以上实施例描述了本发明的基本原理、主要特征及优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书的描述的只是说本发明的原理,在不脱离本发明原理的范围下,本发明还会有各种变化和改进,这些变化和改进均落入本发明保护的范围内。The above embodiments describe the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited by the above-mentioned embodiments. The descriptions of the above-mentioned embodiments and the description only describe the principles of the present invention. Without departing from the scope of the principles of the present invention, there are various Variations and improvements all fall within the scope of the present invention.

Claims (5)

1. A method for synthesizing 2' -spiro substituted three-membered carbocyclic nucleoside 3 has the following reaction equation:
Figure FDA0002515027100000011
wherein R is1Selected from hydrogen, C1-C6 alkyl, alkoxy; r2Selected from C1-C4 alkyl, benzyl, phenyl; r3Selected from benzoyl and tert-butoxycarbonyl;
the method is characterized by comprising the following steps of taking α -pyrimidine substituted acrylate 1 and α -chlorocycloalkanone 2 as raw materials, and reacting in acetonitrile or methanol under the action of potassium tert-butoxide to obtain the spiro pyrimidine nucleoside 3, wherein the reaction temperature is selected from-30 ℃ to-10 ℃.
2. The method of synthesizing a 2' -spirocyclic substituted tri-carbocyclic nucleoside 3 according to claim 1, wherein: r1Selected from methyl, ethyl, hydrogen or methoxy; r2Selected from methyl, ethyl, tert-butyl, phenyl or benzyl.
3. The method according to claim 1, wherein the molar ratio of α -pyrimidine-substituted acrylate 1, α -chlorocycloalkanone 2 to base is 1:1.5: 1.5.
4. A method for synthesizing a 2' -spirocyclic group substituted ternary carbocyclic nucleoside 5, characterized in that: preparing a 2 '-spirocyclic-substituted-ternary carbocyclic nucleoside 3 according to the method of claim 1, followed by adding a reducing agent to the 2' -spirocyclic-substituted-ternary carbocyclic nucleoside 3 to react to obtain a compound 4, followed by deprotection to obtain a compound 5; the reaction equation is as follows:
Figure FDA0002515027100000012
wherein R is1Selected from hydrogen, C1-C6 alkyl, alkoxy; r2Selected from C1-C4 alkyl, benzyl, phenyl; r3Selected from benzoyl and tert-butyloxycarbonyl.
5. The method of synthesizing a 2' -spirocyclic substituted tri-carbocyclic nucleoside 5 according to claim 4, wherein: the reducing agent is selected from sodium borohydride or lithium aluminum hydride; liquid ammonia/methanol or trifluoroacetic acid is selected for deprotection reaction.
CN201910374991.2A 2019-05-07 2019-05-07 Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside Active CN110015996B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910374991.2A CN110015996B (en) 2019-05-07 2019-05-07 Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910374991.2A CN110015996B (en) 2019-05-07 2019-05-07 Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside

Publications (2)

Publication Number Publication Date
CN110015996A CN110015996A (en) 2019-07-16
CN110015996B true CN110015996B (en) 2020-07-28

Family

ID=67193261

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910374991.2A Active CN110015996B (en) 2019-05-07 2019-05-07 Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside

Country Status (1)

Country Link
CN (1) CN110015996B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107602559B (en) * 2017-09-29 2019-10-18 河南师范大学 A method for the synthesis of chiral three-membered carbocyclic nucleosides by asymmetric cyclopropanation initiated by Michael addition
CN108314655B (en) * 2018-03-29 2021-01-15 河南师范大学 A kind of method for synthesizing three-membered carbocyclic pyrimidine nucleoside analogs by rhodium-catalyzed asymmetric cyclopropanation

Also Published As

Publication number Publication date
CN110015996A (en) 2019-07-16

Similar Documents

Publication Publication Date Title
CN108314658A (en) A kind of preparation method of Duo substituted oxazoles derivative
CA2960473A1 (en) Processes for the preparation of tadalafil and intermediates thereof
CN110015996B (en) Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside
CN111995565A (en) A kind of preparation method of (S)-2-piperidinecarboxylic acid
JPH0670049B2 (en) Method for N-alkylation of dihydrolysergic acid
JPS6247190B2 (en)
WO1996026181A1 (en) Aminotetralone derivatives and process for producing the same
Demopoulos et al. Synthesis of 6, 7, 8, 9‐tetrahydro‐N, N‐di‐n‐propyl‐1H‐benz [g] indol‐7‐amine, a potential dopamine receptor agonist
CN111087405B (en) A kind of method for asymmetric synthesis of amaryllidaceae alkaloid (+)-γ-lycorane
CN112142664A (en) A kind of synthetic method of polysubstituted naphthoazepine heterocyclic compounds
CN101454276A (en) Method for the production of 8-aryl-octanoyl derivatives
CN115611894B (en) A nitrogen-containing spirocyclic compound or a pharmaceutically acceptable salt thereof and a preparation method and application thereof
CN108358780B (en) Method for synthesizing highly diastereoselective α-acyl-oxygenated cyclic ketones
CN103936753B (en) Natural products Daldinin and the like total synthesis method
CN115819208B (en) A kind of synthesis method of 2-aryl-3,4-dihydro-1(2H)-naphthone compounds
JP2007051128A (en) Method for producing aniline having aralkyloxy or heteroaralkyloxy group
CN113200902B (en) Polysubstituted pyrrole derivative and preparation method thereof
CN110650735A (en) Highly diastereoselective structures of 4, 5-spirocycles by palladium-catalyzed intramolecular alkenylation
Gonnot et al. Expedient synthesis of mequitazine an antihistaminic drug by palladium catalyzed allylic alkylation of sodium phenothiazinate
CN110963959B (en) Preparation method for synthesizing N-protected and unprotected 3-hydroxy-4, 4-dimethylpiperidine
CN100451010C (en) Method for synthesizing (R)-3-amido tetrahydrofuran
Leeson et al. Transannular reactions of 5-azido-and 5-nitronodibenzo [a, e] cyclooctatrienes and-dibenzo [a, d] cycloheptatrienes. Syntheses of pavine and homoisopavine analogs
CN117924283A (en) Intermediate spiro compound and preparation method thereof
JP4937442B2 (en) Process for producing 5-fluorooxindole
CN115819492A (en) C14 substituted steroid and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant